Novartis faces delay rolling out Galvus

Novartis is staring at some serious problems rolling out its diabetes drug Galvus. New data showing patients taking higher doses of the drug--100 mg--demonstrated more frequent enzyme elevation levels prompted Novartis to seek a revision in prescribing recommendations before the drug is marketed in Europe. The company plans to recommend once or twice daily dosing of 50 mg. That move raised analysts' concerns that Galvus will be less competitive than expected against Merck's once daily Januvia. Novartis had been planning to resubmit Galvus for U.S. approval in 2009. The FDA issued an approvable letter for Galvus earlier this year, outlining a request for additional information.

- see the release from Novartis
- read the report from in-Pharma Technologist

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.